Discover why pharma sector leaders and AI innovation may drive the S&P 500 to 9,000 by 2026. Explore top stocks, growth ...

Some of the best opportunities heading into 2026 may come from stocks that already hold strong market positions but are ...

Looking at options history for Merck & Co (NYSE: MRK) we detected 13 trades. If we consider the specifics of each trade, it is accurate to state that 46% of the investors opened trades with bullish ...

Schwab U.S. Dividend Equity ETF (SCHD) stands out for its much lower fees and higher yield, while ProShares - S&P 500 Dividend Aristocrats ETF (NOBL) features a more concentrated sector mix and ...

Thursday, December 18, 2025 The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including NVIDIA ...

While acknowledging that Keytruda’s loss of exclusivity in 2028 represents the largest patent cliff in biopharma, BMO said it is now confident Merck can replace about 90% of peak Keytruda sales over ...

Antipodes Healthcare Portfolio Manager, Nick Cameron highlighted why Antipodes believes Merck & Co is entering 2026 at an ...

Investors with a lot of money to spend have taken a bullish stance on Merck & Co (NYSE:MRK). And retail traders should know. We noticed this today when the trades showed up on publicly available ...

Merck & Co., Inc. (NYSE:MRK) is one of the stocks Jim Cramer discussed, along with the tech battleground. Cramer highlighted the company’s strategic planning for when Keytruda loses patent protection.

For the better part of a year, Merck & Co. and Halozyme have been locked in an intellectual property disagreement over the the pharma giant's new, under-the-skin version of cancer megablockbuster ...